<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-118564</identifier>
<setSpec>0214-1582</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Chronic tuberculous granulomatous mastitis. Report of 28 cases</dc:title>
<dc:description xml:lang="en">Objectives. To explore the clinical features of tuberculous granulomatous mastitis (TGM), the diagnostic utility of complementary tests, and the results of treatment in a geographical area with a high incidence of tuberculosis. Material and methods. A descriptive, prospective study was performed from January 2010 to May 2012. The diagnosis of tuberculous mastitis was established by identification or culture of Mycobacterium tuberculosis, or by molecular studies (polymerase chain reaction) after Tru-cut biopsy. We also included those patients with granulomatous mastitis without detection of Koch bacillus but who were intense reactors ( &gt;= 15 mm) after inoculation of purified protein derivative. Tuberculosis treatment was administered in the first 2 months with 600 mg of rifampicin, 300 mg of isoniazid, 1,500 mg of pyrazinamide, and 1,200 mg of ethambutol. Subsequently, twice-weekly treatment with 800 mg of isoniazid and 600 mg of rifampicin was administered for 4 months in those patients with total resection of the lesion and for 7 months in patients who did not undergo resection. Results. We included 28 patients. Mammography was performed in 12 patients (42.8%). The lesions were classified as BIRADS 0 (33.3%), BIRADS III (16.7%) and BIRADS IV (50%). Breast ultrasound was performed in all patients. Purified protein derivative was performed in 27 patients (96.4%); 53.6% were intense reactors and 25% were clear reactors. TGM diagnosis was made by histopathology in all patients. Complete lumpectomy was performed prior to the start of tuberculosis treatment in 24 patients (85.8%). There were no recurrences in any of the TGM patients. Conclusions. Due to the low accuracy of imaging techniques, the definitive diagnosis of TGM should be made by histopathological study. In all patients, cure was achieved with the use of oral tuberculosis treatment together with surgery (AU)</dc:description>
<dc:creator>Carrera Palao, Daniel</dc:creator>
<dc:creator>Pinto Paz, Mirian Elizabeth</dc:creator>
<dc:creator>Santa Cruz, Emperatriz</dc:creator>
<dc:creator>Bautista Garcia, Félix</dc:creator>
<dc:creator>Rodriguez Piazze, Lourdes</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. Realizar un estudio de las características clínicas de la mastitis granulomatosa tuberculosa (MGT), la utilidad diagnóstica de las pruebas complementarias y los resultados del tratamiento en un área geográfica con muy alta incidencia de tuberculosis. Material y métodos. Estudio descriptivo, prospectivo, realizado desde enero de 2010 a mayo de 2012. El diagnóstico de mastitis tuberculosa se estableció mediante la identificación o el cultivo de Mycobacterium tuberculosis, o por estudio molecular (reacción en cadena de la polimerasa) tras biopsia con Tru-cut. También se incluyeron aquellas pacientes con mastitis granulomatosa sin detección de bacilo de Koch, reactores intensos &gt;= 15 mm tras la inoculación del derivado proteico purificado. El tratamiento antituberculoso se realizó en los primeros 2 meses mediante rifampicina 600 mg, isoniacida 300 mg, pirazinamida 1.500 mg y etambutol 1.200 mg. Posteriormente, durante 4 meses, 2 veces por semana con isoniacida 800 mg y rifampicina 600 mg, para aquellas pacientes con resección total de la lesión, y durante 7 meses para las pacientes a las que no se realizó exéresis. Resultados. Se incluyeron 28 pacientes. Se realizó mamografía a 12 (42,8%), con lesiones BIRADS 0 (33,3%), BIRADS III (16,7%) y BIRADS IV (50%), y ecografía mamaria a todas las pacientes. El derivado proteico purificado fue realizado a 27 pacientes (96,4%), siendo el 53,6% reactores intensos y el 25% reactores francos. El diagnóstico de MGT se realizó a través de la histopatología en todas las pacientes. Se realizó tumorectomía completa de la lesión previa al inicio del tratamiento antituberculoso en 24 casos (85,8%). No hubo recidiva de la MGT en ninguna paciente. Conclusiones. El diagnóstico definitivo de MGT debe realizarse mediante el estudio histopatológico debido a la baja precisión de las técnicas de imagen. La utilización del tratamiento antituberculoso oral unido a la cirugía logró en todos los casos la curación de la enfermedad (AU)</dc:description>
<dc:source>Rev. senol. patol. mamar. (Ed. impr.);27(1): 27-33, ene.-mar. 2014.</dc:source>
<dc:identifier>ibc-118564</dc:identifier>
<dc:title xml:lang="es">Mastitis crónica granulomatosa tuberculosa. Diagnóstico y tratamiento en 28 casos</dc:title>
<dc:subject>^d12705^s22073</dc:subject>
<dc:subject>^d53986^s22032</dc:subject>
<dc:subject>^d914^s22073</dc:subject>
<dc:subject>^d5069^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8580^s22039</dc:subject>
<dc:subject>^d53986^s22016</dc:subject>
<dc:subject>^d53986^s29166</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d8580^s22045</dc:subject>
<dc:subject>^d999^s22073</dc:subject>
<dc:subject>^d53986^s22012</dc:subject>
<dc:subject>^d7705^s22073</dc:subject>
<dc:subject>^d8580^s22074</dc:subject>
<dc:subject>^d53986^s22009</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:type>article</dc:type>
<dc:date>201403</dc:date>
</metadata>
</record>
</ibecs-document>
